{"entity":{"id":"nct06207656","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initial","aka":["CEBBRA"],"tldr":"A phase 2 trial in colorectal cancer, run by Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), now recruiting.","summary":"Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer is a phase 2, interventional study registered as NCT06207656 by Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), with a registry enrolment figure of 70 participants, started 2024-04-16 and due to reach its primary completion in 2029-04-01. Interventions recorded: EBC. Conditions listed: Colorectal Cancer. Primary outcome: Efficacy of cetuximab in combination with encorafenib plus binimetinib as induction therapy for the treatment of BRAF-V600E mutated MSS aCRC to perform radical treatment of the primary and/or metastases. Colorectal eligibility wording from the registry: \"Participants with histologically or cytologically confirmed colorectal adenocarcinoma\". Sites: Spain. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06207656","url":"https://clinicaltrials.gov/study/NCT06207656"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer","braf-v600e-colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["pierre-fabre"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06207656","phase":"2","setting":"Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","enrolled":70,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06207656/","neighbours":{"cancer":[{"id":"braf-v600e-colorectal","kind":"cancer","name":"BRAF V600E-mutant colorectal cancer","route":"/cancers/braf-v600e-colorectal/"},{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"company":[{"id":"pierre-fabre","kind":"company","name":"Pierre Fabre","route":"/companies/pierre-fabre/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}